Expression of ADAMTS-1, ADAMTS-4, ADAMTS-5 and TIMP3 by hepatocellular carcinoma cell lines

Turner,Sharon  L.; Mangnall,David; Bird,Nigel  C.; Bunning,Rowena  A.D.; Blair-Zajdel,Maria  E.

doi:10.3892/ijo.2012.1525

Expression of ADAMTS-1, ADAMTS-4, ADAMTS-5 and TIMP3 by hepatocellular carcinoma cell lines

Authors:
- Sharon L. Turner
- David Mangnall
- Nigel C. Bird
- Rowena A.D. Bunning
- Maria E. Blair-Zajdel
View Affiliations

Affiliations: Biomedical Research Centre, Sheffield Hallam University, Sheffield, S1 1WB, UK, Liver Research Group, Royal Hallamshire Hospital, University of Sheffield, Sheffield, S10 2JF, UK
Published online on: June 20, 2012 https://doi.org/10.3892/ijo.2012.1525
Pages: 1043-1049

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Little is known about the expression or role of ADAMTS-1, -4 and -5 and their endogenous inhibitor TIMP3 in the liver in physiological and pathological conditions. Their expression was, therefore, investigated in the hepatocellular carcinoma cell lines HepG2 and HuH-7 using qRT-PCR and western blotting, and their cellular localisation by immunocytochemistry. Cytokine treatments were used to assess mRNA and protein modulation. ADAMTS-1, -4, -5 and TIMP3 mRNA and protein were detected in both HepG2 and HuH-7 cells. IL-1β and IL-6 treatments significantly modulated ADAMTS-1 mRNA expression and IL-1β treatment ADAMTS-4 mRNA expression in HepG2 cells. Modulations of mRNA by ≥5-fold did not translate to increased protein expression. This study showed that ADAMTS-1, -4, -5 and TIMP3 were expressed at differential levels in hepatocellular carcinoma cell lines. The pro-inflammatory cytokines IL-1β, TNF-α or IL-6 induced changes in mRNA expression, although these did not translate to the protein level.

View Figures

View References

1.	Wilson JF: Liver cancer on the rise. Ann Intern Med. 142:1029–1032. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Merle P and Trepo C: Molecular mechanisms underlying hepatocellular carcinoma. Viruses. 1:852–872. 2009. View Article : Google Scholar : PubMed/NCBI
3.	Giannelli G and Antonaci S: Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol. 40:842–846. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
5.	Price JT and Thompson EW: Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets. 6:217–233. 2002. View Article : Google Scholar : PubMed/NCBI
6.	Porter S, Clark IM, Kevorkian L and Edwards DR: The ADAMTS metalloproteinases. Biochem J. 386:15–27. 2005. View Article : Google Scholar
7.	Kashiwagi M, Enghild JJ, Gendron C, Hughes C, Caterson B and Itoh Y: Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol Chem. 279:10109–10119. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Bandtlow CE and Zimmermann DR: Proteoglycans in the developing brain: new conceptual insights for old proteins. Physiol Rev. 80:1267–1290. 2000.PubMed/NCBI
9.	Luque A, Carpizo DR and Iruela-Arispe ML: ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF₁₆₅. J Biol Chem. 278:23656–23665. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Hsu Y-P, Staton CA, Cross N and Buttle DJ: Anti-angiogenic properties of ADAMTS-4 in vitro. Int J Exp Pathol. 93:70–77. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Sharghi-Namini S, Fan HP, Sulochana KN, Potturi P, Xiang W, Chong YS, Wang ZY, Wang H and Ge RW: The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor. Biochem Biophys Res Commun. 371:215–219. 2008. View Article : Google Scholar : PubMed/NCBI
12.	Kuno K, Bannai K, Hakozaki M, Matsushima K and Hirose K: The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem Biophys Res Commun. 319:1327–1333. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Held-Feindt J, Paredes EB, Blömer U, Seidenbecher C, Stark AM, Mehdorn HM and Mentlein R: Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int J Cancer. 118:55–61. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 69:562–573. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Lambert E, Dassé E, Haye B and Petitfrère E: TIMPs as multi-facial proteins. Crit Rev Oncol Hematol. 49:187–198. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Bugno M, Witek B, Bereta J, Bereta M, Edwards DR and Kordula T: Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines. FEBS Lett. 448:9–14. 1999. View Article : Google Scholar : PubMed/NCBI
17.	Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
18.	Haddock G, Cross AK, Plum J, Surr J, Buttle DJ, Bunning RAD and Woodroofe NM: Expression of ADAMTS-1, -4, -5 and TIMP-3 in normal and multiple sclerosis CNS white matter. Mult Scler. 12:386–396. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal genes. Genome Biol. 3:Research 0034. 2002. View Article : Google Scholar : PubMed/NCBI
20.	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
21.	Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K and Ikari T: Pathology of hepatocellular carcinoma in Japan. 232 consecutive cases autopsied in ten years. Cancer. 51:863–877. 1983.PubMed/NCBI
22.	Illemann M, Bird NC, Majeed A, Lærum OD, Lund LR, Danø K and Nielsen BS: Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer. 124:1860–1870. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Jones GC and Riley GP: ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther. 7:160–169. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Liu YJ, Xu Y and Yu Q: Full-length ADAMTS-1 and ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene. 25:2452–2467. 2006. View Article : Google Scholar : PubMed/NCBI
25.	Seals DF and Courtneidge SA: The ADAMs family of metalloprotease: Multidomain proteins with multiple functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
26.	Hu B, Kong LL, Matthews RT and Viapiano MS: The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J Biol Chem. 283:24848–24859. 2008. View Article : Google Scholar : PubMed/NCBI
27.	Darnton SJ, Hardie LJ, Muc RS, Wild CP and Casson AG: Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the development of esophageal adenocarcinoma: Loss of expression correlates with poor prognosis. Int J Cancer. 115:351–358. 2005. View Article : Google Scholar : PubMed/NCBI
28.	Hashimoto G, Shimoda M and Okada Y: ADAMTS-4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan. J Biol Chem. 279:32483–32491. 2004. View Article : Google Scholar : PubMed/NCBI
29.	Miyazaki T, Kato H, Nakajima M, Faried A, Takita J, Sohda M, Fukai Y, Yamaguchi S, Masuda N, Manda R, Fukuchi M, Ojima H, Tsukada K and Kuwano H: An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma. Br J Cancer. 91:1556–1560. 2004.PubMed/NCBI
30.	Ryder SD: Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 52:iii1–iii8. 2003. View Article : Google Scholar : PubMed/NCBI
31.	Berasain C, Castillo J, Prieto J and Avila MA: New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int. 153:174–185. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Zimmers TA, McKillop IH, Pierce RH, Yoo J and Koniaris LG: Massive liver growth in mice induced by systemic interleukin 6 administration. Hepatology. 38:326–334. 2003. View Article : Google Scholar : PubMed/NCBI
33.	Masui T, Hosotani R, Tsuji S, Miyamtot Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Koybayashi H, Koizuma M, Toyoda E, Tulachan S, Arii S, Doi R and Imamura M: Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res. 7:3437–3443. 2001.PubMed/NCBI